In the US, Gleevec (imatinib systemic) is a member of the drug class BCR-ABL tyrosine kinase inhibitors and is used to treat Acute Lymphoblastic Leukemia, Chronic Eosinophilic Leukemia, Chronic Myelogenous Leukemia, Dermatofibrosarcoma Protuberans, Gastrointestinal Stromal Tumor, Hypereosinophilic Syndrome, Myelodysplastic Diseases, Myeloproliferative Disorders and Systemic Mastocytosis.
Ingredient matches for Gleevec
Imatinib is reported as an ingredient of Gleevec in the following countries:
- South Africa
Imatinib mesilate (a derivative of Imatinib) is reported as an ingredient of Gleevec in the following countries:
- United States
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.